Evolus Inc (NASDAQ:EOLS) was the target of a large increase in short interest during the month of November. As of November 29th, there was short interest totalling 5,010,000 shares, an increase of 12.1% from the November 14th total of 4,470,000 shares. Currently, 25.1% of the shares of the company are short sold. Based on an average daily trading volume, of 443,800 shares, the days-to-cover ratio is currently 11.3 days.
A number of institutional investors have recently added to or reduced their stakes in EOLS. Metropolitan Life Insurance Co NY purchased a new stake in Evolus in the 1st quarter worth approximately $83,000. Creative Planning purchased a new stake in Evolus in the 2nd quarter worth approximately $318,000. Janney Montgomery Scott LLC increased its holdings in Evolus by 7.7% in the 2nd quarter. Janney Montgomery Scott LLC now owns 24,600 shares of the company’s stock worth $360,000 after acquiring an additional 1,750 shares in the last quarter. Swiss National Bank purchased a new stake in Evolus in the 2nd quarter worth approximately $333,000. Finally, Prime Capital Investment Advisors LLC purchased a new stake in Evolus in the 2nd quarter worth approximately $44,000. 16.94% of the stock is owned by institutional investors.
A number of equities analysts have weighed in on EOLS shares. Svb Leerink started coverage on Evolus in a research report on Tuesday, November 26th. They issued an “outperform” rating and a $25.00 target price for the company. Zacks Investment Research raised Evolus from a “sell” rating to a “hold” rating in a research report on Tuesday, October 15th. HC Wainwright reissued a “buy” rating on shares of Evolus in a research report on Tuesday, November 5th. Mizuho reissued a “buy” rating and issued a $30.00 target price on shares of Evolus in a research report on Thursday, September 5th. Finally, Leerink Swann assumed coverage on shares of Evolus in a research report on Tuesday, November 26th. They set an “outperform” rating and a $25.00 price target for the company. One analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the stock. Evolus has a consensus rating of “Buy” and an average target price of $26.36.
Evolus (NASDAQ:EOLS) last released its quarterly earnings results on Monday, November 4th. The company reported ($0.78) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.33) by $0.55. The business had revenue of $13.17 million for the quarter, compared to analysts’ expectations of $5.18 million. On average, equities analysts anticipate that Evolus will post -3.75 earnings per share for the current year.
Evolus Company Profile
Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Read More: How accurate is the Rule of 72?
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.